tiprankstipranks
Trending News
More News >

Active Biotech Highlights Positive LION Study Results for Laquinimod Eye Drops

Story Highlights
  • Active Biotech is focused on developing immunomodulatory treatments for oncology and immunology.
  • Positive LION study results support further clinical development of laquinimod for uveitis.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Active Biotech Highlights Positive LION Study Results for Laquinimod Eye Drops

Don’t Miss TipRanks’ Half-Year Sale

Active Biotech AB ( (SE:ACTI) ) has shared an update.

Active Biotech announced the availability of an interview with investigators from the LION study, which evaluated the ocular biodistribution of laquinimod eye drops. The study’s positive results support the initiation of a phase II/III clinical program for treating uveitis, highlighting the company’s efforts to find a development partner for further clinical advancement in eye disorders.

More about Active Biotech AB

Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. Their portfolio includes projects such as tasquinimod for myelofibrosis and laquinimod for inflammatory eye disorders, with a core focus on hematological malignancies and eye diseases.

YTD Price Performance: 75.93%

Average Trading Volume: 32,519,021

Current Market Cap: SEK233.7M

Learn more about ACTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1